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Abstract
Background: Previous reports have demonstrated that short durations of vibrotactile stimuli (less
than or equal to 2 sec) effectively and consistently modify both the perceptual response in humans
as well as the neurophysiological response in somatosensory cortex. The change in cortical
response with adaptation has been well established by a number of studies, and other reports have
extended those findings in determining that both GABA- and NMDAR-mediated
neurotransmission play a significant role in the dynamic response of somatosensory cortical
neurons. In this study, we evaluated the impact that dextromethorphan (DXM), an NMDAR
antagonist, had on two distinct vibrotactile adaptation tasks.
Results: All subjects, both those that ingested 60 mg DXM and those that ingested placebo, were
evaluated for their amplitude discriminative capacity between two simultaneously delivered
vibrotactile stimuli both with and without 3 conditions of pre-exposure to adapting stimulation.
The results demonstrated that the perceptual metrics of subjects who ingested 60 mg DXM were
significantly altered from that of controls when the amplitude discrimination task followed one of
the conditions of adapting stimulation. Without the condition of pre-exposure to an adapting
stimulus (or stimuli), there was little difference between the observations obtained from the
subjects that ingested DXM and controls. Peak impact on subject response occurred at 60 min
post-ingestion, whereas the scores of controls who ingested placebo were not impacted.
Conclusion: The results – that DXM blocks vibrotactile adaptation – is consistent with the
suggestion that NMDAR-mediated neurotransmission plays a significant role in the perceptual
adaptive response. This finding is also consistent with neurophysiological findings that report
observations of the effects of NMDAR block on the SI cortical response to repetitive vibrotactile
stimulation.
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Background
Although the effects of conditioning stimuli – or adapta-
tion – have been well documented in a number of sensory
modalities (for review of somatosensory adaptation, see
[1]; for a review of visual adaptation, see [2]), the mecha-
nisms have not been completely elucidated. Moreover,
though there are an exhaustive number of studies that
have explored multiple time courses of changes in cortical
response at both the population and single neuron level,
there have been relatively few studies that have examined
the impact of selective block of different types of neuro-
transmission in the cerebral cortex on sensory perception.
For example, although N-methyl-D-aspartate receptor
(NMDAR) block in the nonhuman primate results in
decreased overall mean firing rate, a contraction of recep-
tive fields, a reduction in the variability of the cortical
response, and a decreased spatial extent in the cortical
response evoked by tactile stimulation [3,4], little is
known about the somatosensory perceptual correlates of
NMDAR block. One finding of interest in the nonhuman
primate studies is that NMDAR block results in a decrease
in the change in responsiveness with repetitive stimula-
tion [4]. In other words, whereas the majority of primary
somatosensory cortical neurons show a significant
decrease in overall mean firing rate evoked by repetitive
vibrotactile stimulation, the application of NMDAR block
results in the majority of these same neurons exhibiting
an absence of this change in overall mean firing rate. In this
study, we sought to observe perceptual correlates of these
changes in cortical activity by characterizing the impact of
NMDAR block on somatosensory adaptation.
Recently we reported that a subject's ability to discrimi-
nate between the amplitudes of two simultaneously deliv-
ered vibrotactile stimuli was highly consistent in healthy
adults such that they yield similar difference limen (DL)
values on this task [5,6]. Additionally, a subject's discrim-
inative capacity was degraded systematically when one of
the stimulus sites was pre-exposed to an adapting stimu-
lus, in a duration-dependent manner [6]. The extremely
low variability of the effects of adaptation on subject per-
formance during this amplitude discrimination task sug-
gested that this protocol could be an extremely reliable
measure for the reduction of perceived intensity caused by
vibrotactile adaptation. The above-referenced method of
single-site adaptation, in parallel with a method that
determines the impact of dual-site adaptation (both in a
dual-site stimulation paradigm), were both used to obtain
observations from two subject groups. One group was
administered placebo and the other group was adminis-
tered dextromethorphan (DXM or DM), a non-opioid
over-the-counter selective NMDAR antagonist. All sub-
jects completed the amplitude discrimination tasks prior
to and after ingestion of either placebo or DXM. The pur-
pose of this study was to investigate the effects of NMDAR
block on the capacity of subjects to discriminate the
amplitude of simultaneous dual-site flutter stimuli with
and without pre-exposure to adapting stimulation, and
the results suggest that NMDAR-mediated neurotransmis-
sion plays a significant role in the perceptual adaptive
response.
Results
Two separate 2AFC tracking protocols (see Methods) were
used to obtain observations of the effects of DXM, an
NMDAR antagonist, on the impact of adaptation on sub-
jects' capacities for discrimination between the ampli-
tudes of two simultaneously delivered vibrotactile
stimuli. In the first protocol, one of the two stimulus sites
that received the vibrotactile stimuli was pre-exposed to
an adapting stimulus, and the tracking protocol targeted
determination of the reduction in perceived intensity at
the adapted stimulus site (for full details, see Methods and
[6]). In the second protocol, both stimulus sites received
adapting stimuli and subsequent test stimuli, but in this
case, both test stimuli were identical and the difference
between the adapting stimuli were tracked, based on sub-
ject response (for full details, see Methods). The working
hypothesis of this protocol was that if the perceived inten-
sities were systematically changed by the adapting stimuli,
then the difference in the two adapting stimuli at the two
sites would result in the subsequent test stimuli being per-
ceived as different, with the test site receiving the larger
adapting stimulus having the weaker perceived intensity.
Results from the single site adaptation protocol
Figure 1 summarizes the average across-subject (n = 11)
performance during both blocks of the single-site adapta-
tion protocol for the placebo Control (n = 9) and DXM (n
= 11) groups at times T0, T1, and T2 (see Methods for
description). Repeated measures ANOVA shows that DLs
were not different between the groups at T0 (p = 0.54 in
Block 1 and p = 0.41 in Block 2). As previously reported
[6], amplitude discrimination was significantly impaired
for both groups with pre-exposure to adapting stimula-
tion (p < 0.01). One interpretation of this graph is that in
Block 2, a 1 sec adapting stimulus reduces the perceived
intensity of the subsequent test stimulus to the extent that
a stimulus with amplitude of approximately 170 μm is
now needed to be perceived nearly the same in intensity
as the standard stimulus (100 μm). Note that in Block 1,
without adaptation, a subject can accurately determine
the difference between a 100 μm and a 120 μm stimulus
that are delivered simultaneously to the two skin sites.
Note that the average post-adaptation DL increased to
approximately 225% above the average DL obtained in
the non-adaptation block.
At time T1 (60 min post-ingestion) DXM drug administra-
tion had a slight effect on amplitude discrimination –BMC Neuroscience 2008, 9:87 http://www.biomedcentral.com/1471-2202/9/87
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though not a significant one – as indicated by Block 1 data
(p = 0.57). However, in the adaptation phase of the run
(Block 2) the data from the DXM group demonstrated a
significantly reduced impact of adaptation compared to
the control group as shown in Block 2 (p < 0.01). The
average post-adaptation DL for the control group
remained at a level that was over 200% above the values
obtained in block 1, yet the average post-adaptation DL
for the DXM group was only approximately 67% above
the block 1 values. Thus, as a group, subjects that ingested
DXM experienced less adaptation, and subsequently per-
formed better at the post-adaptation amplitude discrimi-
nation task than did the control group.
Two hours post ingestion (T2), there was very little differ-
ence between the amplitude discrimination performance
of the DXM and control group (as shown in Block 1
results). In the post-adaptation amplitude discrimination
task (as shown in Block 2 results), the DXM group
appeared to still be slightly outperforming the control
subjects, although there were no significant differences
observed between the two groups for this data set (p =
0.092), as it appears that the drug was nearing the end of
its effectiveness.
Results from the dual site adaptation protocol
Subject performance on the dual-site adaptation protocol
is summarized in Figure 2. Interpretation of these results
Comparison of difference limen (DL; with s.e. bars) between the Control and DXM groups for amplitude discrimination with  single-site adaptation at times T0, T1, and T2 Figure 1
Comparison of difference limen (DL; with s.e. bars) between the Control and DXM groups for amplitude discrimination with 
single-site adaptation at times T0, T1, and T2. No adapting stimulus was applied to either stimulus site in Block 1, and no differ-
ence was observed between the two groups at any time for Block 1. The test condition in Block 2 was preceded by an adapting 
stimulus (1 sec in duration) at the site of the test stimulus. Note that at T1, in Block 2, performance between the groups was 
significantly different (* ANOVA; p < 0.01). At T2, Block 2 performance values for the DXM group return to baseline levels (p 
= 0.092).
Comparison of difference limen (DL; with s.e. bars) between the control group and the DXM group for amplitude discrimina- tion with dual-site adaptation at times T0, T1, and T2 (see Methods for description) Figure 2
Comparison of difference limen (DL; with s.e. bars) between the control group and the DXM group for amplitude discrimina-
tion with dual-site adaptation at times T0, T1, and T2 (see Methods for description). DLs are shown for two conditions of adapt-
ing stimulus duration: 500 and 2000 msec. Note that at T1, performance was significantly degraded for the DXM group under 
both conditions of adapting stimulus duration (p < 0.01). DLs show signs of recovering to baseline levels at T2, although they 
remain significantly elevated at that time (p < 0.01).BMC Neuroscience 2008, 9:87 http://www.biomedcentral.com/1471-2202/9/87
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is slightly different than in the above-described data set. In
this case, the "standard" adapting stimulus amplitude is
constant at 50 μm and a "test" adapting stimulus initially
at 150 μm is increased or decreased, based on subject
response to which test stimulus felt more intense. The DL
was determined by the tracked difference between the
"standard" adapting stimulus and "test" adapting stimu-
lus at which the test stimuli felt identical. With the adap-
tation duration of 500 msec, subjects in both groups
perceived a difference between the test stimuli at an adap-
tor DL of approximately 80 μm. When the adaptation
duration was increased to 2000 msec, the DL was reduced
to approximately 65 μm. Thus, at T0, both groups showed
significant improvement at amplitude discrimination (of
identical stimuli) when the adapting stimulus duration
was increased from 500 msec to 2000 msec (p < 0.01),
and no difference in performance was observed between
the groups for each of these two conditions (p = 0.49 and
p = 0.32, respectively).
The performance observed in the drug absent condition
was significantly degraded 60 min after DXM ingestion
(T1) under both durations of adapting stimulation at (p <
0.01; Figure 2, middle panel). With DXM, subjects per-
ceived a difference between the test stimuli at a difference
in adapting amplitudes of approximately 120 μm with the
500 msec adapting stimulus duration (compare with 80 at
T0 – approximately a 45% increase in the DL with DXM)
and approximately 105 μm with the 2000 msec adapting
stimulus duration (compare 65 μm at T0 – approximately
a 66% increase in the DL with DXM). At T2, or 120 min-
utes post-ingestion, these differences between the DXM
and Control groups appear to be decreasing, although
they remain significantly different (p < 0.01). The contrast
between these measures, obtained with the dual site adap-
tation protocol and those obtained with the single site
adaptation protocol, suggests that the results obtained
with dual site adaptation may be more sensitive in detect-
ing differences in the impact of the DXM on adaptation.
Discussion
In the present study, we investigated the effects of dex-
tromethorphan (DXM), an NMDAR antagonist, on the
ability of subjects to discriminate between the amplitude
of two simultaneously delivered vibrotactile stimuli with/
without pre-exposure to adaptation stimulation. The
results show that the DXM drug administration had no
effect on the subjects' performance on a standard ampli-
tude discrimination task, but it significantly reduced the
impact of adaptation on amplitude discrimination, and
this reduction began to recover two hours after the inges-
tion of DXM.
Under control conditions (placebo instead of DXM), the
observed impairment in amplitude discrimination
induced by adaptation is consistent with a previously
published report, which demonstrated that a subject's
ability to accurately discriminate differences in the ampli-
tude of two simultaneously delivered vibrotactile stimuli
was significantly degraded with prior exposure to an
adapting stimulus at the test stimulus site [6]. Tommer-
dahl and colleagues proposed that the effect of adaptation
on amplitude discrimination capacity was due to an ele-
vation of the detection threshold, and thus a reduction in
the perceived intensity of a subsequent stimulus, induced
by the adapting stimulus. This phenomenon has been
characterized in a large body of psychophysical studies [7-
9] that reported that when the adapting stimulus is
increased in duration or amplitude, the perceived inten-
sity evoked by subsequent test stimuli is reduced. A
number of neurophysiological studies have demonstrated
that the effects of reduced intensity due to adapting stim-
ulation are possibly attributable to a reduction in the
responsivity of central neurons or in synaptic processes
associated with the central neurons after prolonged or
repetitive stimulation. More specifically, O'Mara and col-
leagues [10] found that extended exposure to a vibratory
stimulus produced substantial reductions in the respon-
sivity of neurons in the cuneate nucleus, but not in the
peripheral afferents. Lee and Whitsel [11] reported that
repetitive brushing stimuli frequently lead individual SI
neurons and neuron groups to modify their response to
the repetitive afferent drive. Additionally, Lee and Whitsel
[12] found that the majority (~58%) of the SI neurons
sampled showed a decreased response to repetitive stimu-
lation (3–5 Hz) of their receptive fields. In that report, it
was proposed that the glutamate-mediated excitatory
effects on NMDAR are to a large extent responsible for the
appreciable capacities of cortical neurons to modify their
physiological properties with repetitive sensory experi-
ence.
It is important to note that the spatial and temporal pat-
terns of responses in primary somatosensory cortex (SI) to
repetitive vibrotactile stimulation are largely dependent
on the complex interplay of GABA-mediated inhibition
[13] and NMDAR activation [14] in addition to other neu-
ral processes [15,16]. The specific contribution of
NMDARs to the response evoked by non-noxious tactile
stimulation has been described by relatively few studies.
Duncan et al systemically administered ketamine, a non-
competitive NMDAR antagonist, in nonhuman primates
and found that the responsivity, receptive field (RF) size,
and mean firing rate (MFR) of SI neurons evoked by tac-
tile stimulation were reduced in a dose- and time-depend-
ent fashion [3]. Similarly, Whitsel et al [4] examined
cortical (SI) neuron activity evoked by skin brushing stim-
ulation and, using intravenous ketamine or phencyclidine
(PCP) for NMDAR block, found the SI response to be
NMDAR dependent and that SI neuron mean firing rateBMC Neuroscience 2008, 9:87 http://www.biomedcentral.com/1471-2202/9/87
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did not diminish with repetitive stimulation in the pres-
ence of NMDAR block. Based on their results, they pro-
posed that in the presence of NMDAR block, normal
pericolumnar interactions within the cerebral cortical net-
works become disrupted and the predominant excitatory
drive of each SI neuron is conveyed by direct thalamocor-
tical connections acting via AMPA receptors. However, at
the same time, the response to that direct drive becomes
partially suppressed by the lateral inhibitions derived
from the co-activated columns that surround it, which are
mediated via NMDAR on the local GABAergic interneu-
rons. As a result, the systemic administration of an
NMDAR antagonist is expected to reduce lateral inhibi-
tion on the pyramidal neurons of the directly activated
column, but allow a full expression of the direct thalamo-
cortical excitatory drive during skin stimulation. Observa-
tions obtained from 2DG, optical imaging and RF studies
in the presence of NMDAR block were also consistent
with these findings [13,16-19]. To summarize, the time
dependent changes often observed in SI cortical response
to repetitive stimulation were not observed with NMDAR
block. Longer duration time dependent effects on tactile
perception have also been demonstrated to be signifi-
cantly impacted by NMDAR block [20].
Similar observations in reduction of adaptation to vibro-
tactile stimulation have been observed in autism [21,22].
However, in those studies, it was concluded that this
reduction in adaptation was due to compromised or
below-normal GABA-mediated neurotransmission in sub-
jects with autism, a finding consistent with a number of
reports in the autism literature ([22-28]; also see, for dis-
cussion: [23,29]). Both the reduction of the impact of
adaptation on amplitude discrimination in the presence
of DXM and a similar reduction observed in subjects with
compromised GABA levels supports the model of
dynamic cortical response to repetitive stimulation put
forth by Whitsel and colleagues [15] and later expanded
by Kelly and Folger [30]. One of the key elements of that
model is that cortical responses in somatosensory cortex
to repetitive stimulation are shaped by dynamic perico-
lumnar lateral interactions mediated by both GABA and
NMDAR neurotransmission.
In short, without NMDAR mediated activity, the level of
excitation required to evoke inhibitory responses
becomes diminished, and the GABA-mediated activity
required to diminish the cortical responses evoked by
repetitive stimuli becomes weaker. Thus, with NMDAR
block, although the overall cortical response is weaker, the
change of the response caused by conditioning or adapt-
ing stimuli is significantly reduced. It should be noted that
although DXM does have effects other than that of an
NMDAR antagonist, the known effects of DXM as an
NMDAR antagonist are consistent with the impact of
NMDAR block on centrally mediated neurotransmission.
The observation of weakened adaptation response – to
repetitive stimulation in populations whose GABA- or
NMDAR-mediated neurotransmission has been compro-
mised – appears to strengthen the original proposal by
Whitsel and colleagues that the adaptive changes
observed in sensory perception at short stimulus dura-
tions (less than 5 seconds) are principally centrally medi-
ated.
Conclusion
The results – that DXM blocks vibrotactile adaptation – is
consistent with the suggestion that NMDAR-mediated
neurotransmission plays a significant role in the percep-
tual adaptive response. This finding is also consistent with
neurophysiological findings that report observations of
the effects of NMDAR block on the SI cortical response to
repetitive vibrotactile stimulation.
Methods
Twenty subjects (21–27 years in age) were studied who
were naïve both to the experimental design and issue
under investigation. The subjects consisted of 6 males and
5 females that received DXM during the testing session,
and 5 males and 4 females that received placebo, all right-
hand dominant. The study was performed in accordance
with the Declaration of Helsinki, all subjects gave their
written informed consent, and procedures were reviewed
and approved in advance by an institutional review board.
Two separate two-alternative forced choice (2AFC) track-
ing protocols were used to evaluate the effects of adapta-
tion on amplitude discriminative capacity of each subject.
Each subject fasted for 2 hours prior to the study begin-
ning. Upon arrival, the subject was seated comfortably in
a chair with the left arm resting on a table surface. The
subject's left hand was placed under a dual-site portable
vibrotactile stimulator (CM-1; for full description, see
[5]). Two probe tips (5 mm diameter) were positioned 30
mm apart along a transversally oriented linear axis along
the hand dorsum. Previous studies have demonstrated
that, for 25 Hz flutter stimuli, (i) the distance at which the
two stimuli were positioned apart on the hand dorsum
(30 mm) is well outside a subject's two point limen
[31,32] and (ii) at a 30 mm probe separation there is no
difference in the ability of a subject to detect a difference
in the amplitudes of flutter stimulation applied simulta-
neously or sequentially to the 2 skin sites [5]. The hand
dorsum was selected to receive the stimulation because: 1)
innervation density across this skin region remains rela-
tively constant, 2) the surface is easily accessible and per-
mits convenient stimulator placement, 3) the surface is
relatively flat, reducing confounds of skin curvature
present at other potential sites of stimulation, 4) it per-
mits positioning of the subject's arm and hand in a com-BMC Neuroscience 2008, 9:87 http://www.biomedcentral.com/1471-2202/9/87
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fortable and stable position for the full duration of an
experimental session and, 5) perhaps most importantly,
there is very little, if any between-subject use-dependent
changes in sensitivity at this particular site. Previous stud-
ies have demonstrated that human subjects demonstrate
very consistent performance (yield similar DLs) with sim-
ilar amplitude discrimination tasks on the hand dorsum
[5,6,21,22,31-33]. One significant aspect of those previ-
ous studies was that consistent results were obtained
although stimulus positions were randomly located on a
trial-by-trial basis, and thus, the relatively large size of the
probe tip apparently compensates for the differential dis-
tribution of bone vs. muscle across the hand dorsum.
Visual cueing was provided with a computer monitor dur-
ing the experimental runs. Specifically, an on-screen light
panel was used to indicate to the subject when the stimu-
lus was on and when the subject was to respond. The sub-
ject was not given performance feedback or knowledge of
the results during the data acquisition until all runs were
completed. At the start of each run, the two probe tips
were driven towards the skin until each tip registered a
force of 0.1 g, as determined by a closed-loop algorithm
in the CM-1 stimulator feedback system. The tips were
then further indented into the skin by 500 μm to insure
good contact with the skin. An audiometer was used to
insure that no auditory cues were emitted from the stimu-
lator during delivery of the range of stimuli used in this
study. Practice trials were used to familiarize the subject
with simultaneous two-site amplitude discrimination and
correct responses on 5 consecutive trials were required
before commencing with the first session. Each subject
completed three experimental sessions. The first session
(T0) was conducted prior to ingestion of any drug medi-
cation or placebo. After the first session was complete, a
subject ingested either 60 mg of NMDAR antagonist DXM
or a placebo. The placebo drug was perceptually similar to
DXM in shape, color, texture, and taste and the subjects
ingested their respective capsules with eyes closed. The
study was conducted in a double-blind fashion such that
neither the subject nor the experimenter was aware of the
actual drug (DXM or placebo) being administered. One
hour post-ingestion (T1), each subject was re-tested using
the same protocol. Finally, after one additional hour (T2),
the subjects were tested a third time to observe the effects,
if any, of recovery. Each individual subject session lasted
approximately 15 min (total time of 2.5 hours including
experimental runtime and breaks) and the subject per-
formed desk work, unrelated to the study, between each
session. Each session consisted of two separate 2AFC pro-
tocols – one tested the effects of single-site adaptation on
dual-site simultaneous amplitude discrimination (previ-
ously reported in [5,6]), and the other protocol obtained
observations of the impact of simultaneous dual-site
adaptation effects on an amplitude discrimination task.
Single-site adaptation
During the first run of each session, a tracking protocol,
40 trials total, was implemented that consisted of 2
sequential blocks (see Figure 3; not drawn to scale). This
protocol has been described in detail in previous reports
[5,6]. In the first block, a vibrotactile test stimulus (25
Hz, amplitude between 105–200 μm) was delivered to
one skin site at the same time that a standard stimulus (25
Hz, amplitude fixed at 100 μm) was applied to the other
skin site. The loci of the test and standard stimuli were
Schematic of the protocol used for amplitude discrimination with single-site adaptation Figure 3
Schematic of the protocol used for amplitude discrimination with single-site adaptation. Two blocks of stimulus delivery were 
employed. In Block 1, two 25 Hz vibrotactile stimuli, the standard (S) and test (T), were delivered at the same time for 0.5 sec. 
A 5 sec delay (excluding subject response interval (RI)) was imposed before onset of the next trial. In Block 2, single-site adapt-
ing stimulation was first delivered for 1 sec, followed by a 1 sec inter-stimulus interval, and then the standard and test stimuli.BMC Neuroscience 2008, 9:87 http://www.biomedcentral.com/1471-2202/9/87
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randomly selected on a trial-by-trial basis. Stimulus dura-
tion was 0.5 sec, followed by subject response (the subject
was queried to select, using a two-button switchbox, the
skin site that received the most intense stimulus) and a 5
sec delay before onset of the next trial. Subjects were not
provided any feedback during an experimental run. At the
beginning of the experimental run, the test stimulus was
200 μm (peak-to-peak amplitude) and the standard was
100 μm. In the intial 10 trials, the difference in the ampli-
tudes of the test and standard stimuli was adjusted on the
basis of the subject's response in the preceding trial using
a 1-up/1-down algorithm (the difference in amplitude
was decreased if the subject's response in the preceding
trial was correct; it was increased if the response was incor-
rect). After the initial 10 trials were completed, test stimu-
lus amplitude was modified using a 2-up/1-down
algorithm – in these trials two correct/one incorrect sub-
ject response(s) resulted in a decrement/increment,
respectively, in the amplitude difference between the test
and standard stimuli. This approach was selected because
it enabled rapid determination ("tracking") of each sub-
ject's minimally detectable difference in the amplitudes of
two-site skin flutter stimulation [5]. On average, approxi-
mately 7 reversals occurred before the conclusion of the
tracking series. The step size was held constant throughout
all experimental runs at 10 μm.
In the second block (adaptation block), delivery of the
test and standard stimuli was preceded by adapting stim-
ulation at one of the stimulus sites. Specifically, a 25 Hz
100 μm adapting stimulus at the location of the test stim-
ulus was delivered for 1 sec prior to the presentation of the
test and standard stimuli. By presenting the adapting stim-
ulus to the same site as the test stimulus, it was possible to
quantify the effect of reduced perceived intensity due to
adapting stimulation. The duration of adapting stimula-
tion delivered was 1 sec. A 2-up/1-down algorithm was
used in Block #2 to track the subject's ability to determine
the most intense stimulus, and the initial conditions of
Block #2 were the final conditions of Block #1.
Dual-site adaptation
A separate 2AFC tracking protocol was also administered
during each session (see Figure 4; not to scale). In this
case, two adapting stimuli – of different amplitudes –
were presented at the two stimulus sites prior to two sub-
Schematic of the protocol used for amplitude discrimination with dual-site adaptation Figure 4
Schematic of the protocol used for amplitude discrimination with dual-site adaptation. During the adapting interval (A), two 
adapting stimuli, always of different amplitude, were delivered simultaneously to the skin, followed by a 1 sec ISI. During the 
test interval (T), a pair of identical test stimuli was delivered simultaneously to the same two skin sites. The subject was que-
ried to select in each trial the skin site that received the most intense test stimulus. A correct response was registered when 
the subject chose the test stimulus that was delivered to the same location as the adapting stimulus of lower amplitude.BMC Neuroscience 2008, 9:87 http://www.biomedcentral.com/1471-2202/9/87
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sequent test stimuli of equal amplitude. A schematic of
example trials during the dual-site adaptation protocol is
shown in Figure 4. During the adaptation interval (A), two
adapting stimuli, always of different amplitude, were
delivered simultaneously to the skin. One adapting stim-
ulus was held at constant 50 μm amplitude, and the other
adapting stimulus had initial amplitude of 150 μm that
was varied during the experimental run dependent upon
subject response. The loci of the two adapting stimuli
were randomly selected on a trial-by-trial basis. The adapt-
ing stimuli were followed by a 1 sec inter-stimulus interval
(ISI). During the test interval (T), a pair of identical 100
μm test stimuli was delivered simultaneously for 500
msec to the same two skin sites. During the response inter-
val (RI), the subject was queried to select, using a two-but-
ton switchbox, the skin site that was perceived to receive
the most intense stimulus. The subject response was fol-
lowed by a 5 sec inter-trial interval (ITI), after which the
subsequent trial began. In the first trial of the 20-trial
experimental run, the variable adapting stimulus ampli-
tude was set to 150 μm, and throughout the run this
amplitude was always ≥ 55 μm. Note that a correct
response was registered when the subject chose the test
stimulus that was presented to the skin site to which the
adapting stimulus of lower amplitude was presented. The
step size was held constant throughout the dual-site adap-
tation experimental runs at 5 μm. Two conditions of
adapting stimulus duration were implemented in separate
conditional runs, randomized in order: 500 msec and
2000 msec. The working hypothesis of this protocol was
that subjects would perceive a stimulus as more intense if
it were delivered at the site that received the weaker of the
two adapting stimuli.
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